藏药柳茶提取物对非酒精性脂肪肝病大鼠肝脏脂肪代谢的影响  

Effects of Liucha extract on liver lipid metabolism in rats with nonalcoholic fatty liver disease

作　　者：马晓燕[1] 王晶宇[1] 卢岩松[2] 田青山[2] 夏苗[1] 刘昕[1] 

机构地区：[1]兰州大学基础医学院病理生理学研究所,甘肃省兰州市730000 [2]青海省人民医院外科,青海省西宁市810000

出　　处：《世界华人消化杂志》2010年第26期2739-2744,共6页World Chinese Journal of Digestology

基　　金：国家首届大学生创新计划基金资助项目;No.860014;甘肃省中药管理局科技攻关基金资助项目;No.GZK-2008-20~~

摘　　要：目的:研究柳茶提取物对非酒精性脂肪肝病大鼠肝脏脂肪代谢的影响.方法:高脂饲料饲养SD大鼠,6wk后建立非酒精性脂肪肝病模型.随机分为4组:模型组、柳茶提取物低、中、高剂量组,另设正常对照组.分别给相应干预8wk后处死,测血丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)水平及肝匀浆脂肪含量;制作肝组织切片在光镜下观察形态变化;实时荧光定量RT-PCR法测肝脏脂肪代谢关键酶PPARα、ACOmRNA表达量,Westernblot检测PPARα蛋白表达水平.结果:与模型组相比,柳茶提取物各剂量组肝功能有不同程度好转,与模型组比较,柳茶提取物低、中剂量组ALT、AST水平均明显降低,有统计学差异(29.83mmol/L±2.78mmol/L,25.78mmol/L±2.63mmol/Lvs31.90mmol/L±2.52mmol/L;110.53mmol/L±12.33mmol/L,100.45mmol/L±12.57mmol/Lvs128.61mmol/L±16.01mmol/L,P<0.05或0.01);肝匀浆中柳茶提取物中剂量组胆固醇(CHOL)及三酰甘油(TG)含量均较模型组明显下降,差异具有统计学意义(0.30mmol/L±0.02mmol/Lvs0.47mmol/L±0.04mmol/L,0.75mmol/L±0.06mmol/Lvs0.85mmol/L±0.04mmol/L,P<0.01或0.05).肝细胞形态学改善以柳茶提取物中剂量组表现最为显著,肝细胞内脂滴消失,无炎性细胞浸润及细胞坏死,胞质疏松,肝窦增宽;与模型组相比,柳茶提取物中、高剂量组PPARα、ACOmRNA表达量增加(均P<0.01);柳茶组PPARα蛋白与模型组相比有不同程度的增加,且与柳茶剂量呈正相关,剂量越大,PPARα蛋白的表达量也越大.结论:柳茶提取物可上调脂肪代谢关键酶PPARα、ACOmRNA水平,促进PPARα蛋白合成,增强非酒精性脂肪肝大鼠肝脏脂肪酸氧化,改善肝功能.AIM： To investigate the effect of Liucha extract on liver lipid metabolism in rats with nonalcoholic fatty liver disease. METHODS： A rat model of nonalcoholic fatty liver disease was established by feeding rats a high-fat diet for 6 wk. The model rats were divided randomly into four groups： model group and low-, medium- and high-dosage treatmentgroups. The treatment groups were intragastrically given different doses of Liucha extract for 8 wk. A normal control group was also run. All rats were killed at week 8. Liver function parameters （ALT, AST） and the contents of fat （CHOL, TG） in liver homogenate were examined. Hepatic morphological changes were observed under a light microscope. The expression of PPARα and ACO mRNAs and PPARα protein was measured by RT-PCR and Western blot, respectively. RESULTS： Compared with the model group, liver function was improved in the treatment groups. The levels of ALT and AST were significant lower in the low- and medium-dosage treatment groups than in the model group （29.83 mmol/L ± 2.78 mmol/L and 25.78 mmol/L ± 2.63 mmol/L vs 31.90 mmol/L ± 2.52 mmol/L; 110.53 mmol/L ± 12.33 mmol/L and 100.45 mmol/L ± 12.57 mmol/L vs 128.61 mmol/L ± 16.01 mmol/L; all P 0.05 or 0.01）. The contents of CHOL and TG in liver homogenate were significantly lower in the medium-dosage treatment group than in the model group （0.30 mmol/L ± 0.02 mmol/L vs 0.47 mmol/L ± 0.04 mmol/L, 0.75 mmol/L ± 0.06 mmol/L vs 0.85 mmol/L ± 0.04 mmol/L, both P 0.01 or 0.05）. Hepatic morphological changes were improved in the treatment groups, particularly prominent in the medium-dosage treatment group. Compared with the model group, the expression of PPARα and ACO mRNAs was upregulated in the medium- and high-dosage treatment groups （both P 0.01）. In addition, Liucha extract up-regulated the expression of PPARα protein in a dosage-dependent manner. CONCLUSION： Liucha extract could up-regulate the mRNA expression of PPARα and ACO, enhance the synthesis of PPARα protein, promo

关 键 词：柳茶提取物 大鼠 非酒精性脂肪肝病 

分 类 号：R29[医药卫生—民族医学]